Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

prasugel vs ticagrelor angioplastyNo randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out in the last 7 years since these newer P2Y12 inhibitors first showed a higher efficacy relative to clopidogrel.

 

This study was designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with acute myocardial infarction treated with primary angioplasty.

 

A total of 1230 patients were enrolled and randomized to receive one drug or the other; treatment begun before the procedure.

 

Nearly 4% of infarctions were in cardiogenic shock and 5.2% required mechanical ventilation.

 

The primary endpoint was defined as death, re-infarction, urgent revascularization, stroke, major bleeding or extended hospitalization (beyond 7 days).

 

This analysis presents data from the first 30 days, but the total follow-up planned is 1 year and will be completed by 2017.

 

The study was prematurely terminated due to the wide similarity between these drugs. The primary endpoint was 4% for prasugrel vs. 4.1% for ticagrelor (odds ratio [OR]: 0.98; 95% confidence interval [CI]: 0.55 to 1.73; p = 0.939). No significant difference was observed in any of the different components of the primary endpoint.

 

At 30 days, the secondary endpoint composed of cardiovascular death, non-fatal infarction, or stroke did not show any significant difference between these drugs (prasugrel 2.7% vs. ticagrelor 2.5%; OR: 1.06; p = 0.864).

 

Conclusion

This head-to-head comparison of prasugrel and ticagrelor did not show any difference between these drugs regarding efficacy or safety in patients with acute myocardial infarction undergoing primary angioplasty.

 

The rates of major events were similar, although with broad confidence intervals around the estimates. In consequence, these observations must be confirmed in a larger study.

 

Original title: Prasugrel Versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Multicenter Randomized PRAGUE-18 Study.

Reference: Motovska Z et al. Circulation. 2016 Nov 22;134(21):1603-1612.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....